Cartography
Cancer Treatment Developer
Adaptive Biotechnologies
Clinical Diagnostic Equipment Developer
Gilead Sciences
Innovative Drug Developer, Distributor
2026Year1Month6On [date], Pfizer announced its collaboration with the U.S. biotech companyCartography BiosciencesReach a cooperation agreement in the cancer field, focusing on the discovery and validation of tumor-selective antigens, with a total cooperation amount up to8.65Billion USD, triggering widespread attention in the industry.
According to the terms of the agreement, Pfizer will provide funding to Adaptive Biotechnologies Corporation, headquartered in California.CartographyPay the Most6500Million-dollar upfront payment, near-term milestone payments, and option exercise fees to support the research and development of tumor-selective antigens in specific disease areas.
If all collaboration options are exercised and all milestone targets are achieved,CartographyWill accumulate up to8.65In addition to the payment of USD billion, it will also enjoy a tiered royalty based on the net sales of the product.
In this collaboration,CartographyWill Utilize Its Core Drug Discovery Platform——AtlasAndSummit, and carry out the screening and validation of tumor-selective antigens and antigen pairing. These two platforms are built on massive datasets, covering cell state information from hundreds of thousands of healthy individuals and large-scale tumor cell atlas data. They can overcome the limitations of traditional tools, analyze deeper target biological mechanisms, and thereby improve treatment precision and patient prognosis.
CartographyChief Executive Officer and Co-FounderKevin ParkerThe doctor said that the unique advantages of the platform would bring new breakthroughs in targeted cancer therapy.
Under the cooperation framework, this multi-year partnership will grant Pfizer options for multiple antigens. Once Pfizer selects relevant candidate targets, it will fully take over the subsequent development and commercialization of the corresponding projects.
Notably, this is not Pfizer's only major move in the biotech field recently. Just weeks ago, Pfizer had just partnered with Seattle'sAdaptive BiotechnologiesReach cooperation and leverage its customizationTCell Receptor Discovery Engine and Large-Scale Immune Receptors-Antigen mapping data, deeply focused on the field of autoimmune diseases, with a collaboration amount similarly as high as8.9Billion US dollars.
AndCartographyAs a rapidly growing biotech company, it has long gained the favor of industry giants.2024In that year, the company collaborated with Gilead Sciences to jointly develop drugs targeting triple-negative breast cancer and common non-small cell lung cancer. Gilead Sciences made a payment at that time.2000Million USD upfront payment, subsequent milestone payments not publicly disclosed.
In terms of pipeline progress,CartographyCore Candidate DrugCBI-1214is a product targeting colorectal cancer.TCell Adaptor.2025Year12In that month, the drug was approved by the United States.FDAApproval for EntryIPhase clinical trials, while simultaneously being granted Fast Track designation to expedite its development and review process. In addition, the company’s pipeline includes several early-stage antibody-based cancer therapies, with the core objective of developing more precise tumor-targeted drugs than current treatment options.
CartographyIn2022Ended stealth mode in the same year, and completed5700Million USDARound of financing;2025In that year, the company completed6700Million USDBThis round of financing was led by Pfizer's venture capital department, laying the foundation for the in-depth cooperation between the two parties.
This time, Pfizer andCartographyThe strong collaboration not only highlights the significant value of tumor-selective antigens as core targets in targeted therapy but also reflects an industry trend where multinational pharmaceutical companies accelerate breakthroughs in cancer treatment by partnering with innovative biotech firms and integrating cutting-edge technology platforms. As the collaboration progresses, it is expected to bring more precise and effective new treatment options to cancer patients.
